Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma

American Journal of Pathology

Volumn 178, Issue 2, 2011, Pages 853-860

  Roos, Frederik C ^a,b   Evans, Andrew J ^a,c   Brenner, Walburgis ^b   Wondergem, Bill ^d   Klomp, Jeffery ^b   Heir, Pardeep ^a   Roche, Olga ^a   Thomas, Christian ^b,d   Schimmel, Heiko ^e   Furge, Kyle A ^b   Teh, Bin T ^d   Thüroff, Joachim W ^b   Hampel, Christian ^b   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; E2 EPF PROTEIN; GENE PRODUCT; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PARAFFIN; PROTEASOME; UBE2S PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; FEMALE; FOLLOW UP; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PAPILLA; MALE; NEPHRECTOMY; NUCLEOTIDE SEQUENCE; OXYGEN SENSING; PAPILLARY RENAL CELL CARCINOMA; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN TARGETING; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 79951841267     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.10.033     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249
2. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K: Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:987-989
3. Reuter VE: The pathology of renal epithelial neoplasms. Semin Oncol 2006, 33:534-543
4. Delahunt B, Eble JN: Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997, 10:537-544 (Pubitemid 27293491)
5. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS: Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009, 15:1162-1169
6. Rosner I, Bratslavsky G, Pinto PA, Linehan WM: The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 2009, 27:131-136
7. Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R: Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009, 40:10-29
8. Koivune P, Hirsila M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J: Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 2007, 282:4524-4532 (Pubitemid 47100953)
9. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP: VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010, 221:125-138
10. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2:423-427
11. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel- Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472 (Pubitemid 32335942)
12. Kaelin WG, Jr.: Molecular basis of the VHL hereditary cancer syndrome, Nat Rev Cancer 2002, 2:673-682
13. Roberts AM, Ohh M: Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 2008, 20:83-89 (Pubitemid 350190986)
14. Rini BI, Campbell SC, Escudier B: Renal cell carcinoma. Lancet 2009, 373:1119-1132
15. Jung CR, Hwang KS, Yoo J, Cho WK, Kim JM, Kim WH, Im DS: E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 2006, 12:809-816 (Pubitemid 44050071)
16. Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, Sufan RI, Roberts AM, Wilson LA, Betten M, Vandewalle C, Berx G, Marsden PA, Irwin MS, Teh BT, Jewett MA, Ohh M: VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 2007, 27:157-169 (Pubitemid 46013241)
17. Stickle NH, Cheng LS, Watson IR, Alon N, Malkin D, Irwin MS, Ohh M: Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat Res 2005, 578:23-32
18. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT: A molecular classification of papillary renal cell carcinoma. Cancer Res 2005, 65:5628-5637 (Pubitemid 40911163)
19. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM: Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res 2003, 9:1441-1445 (Pubitemid 36418399)
20. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26:127-131
21. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002, 20:2376-2381 (Pubitemid 34441667)
22. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918 (Pubitemid 41103603)
23. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, Kahnoski R, Yang XJ, Teh BT: Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007, 67:3171-3176 (Pubitemid 46724854)
24. Sanders ME, Mick R, Tomaszewski JE, Barr FG: Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 2002, 161:997-1005 (Pubitemid 34988387)
25. Patocs A, Gergics P, Balogh K, Toth M, Fazakas F, Liko I, Racz K: Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family. BMC Med Genet 2008, 9:29
26. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004 (Pubitemid 46646218)
27. Lim JH, Jung CR, Lee CH, Im DS: Egr-1 and serum response factor are involved in growth factors- and serum-mediated induction of E2-EPF UCP expression that regulates the VHL-HIF pathway. J Cell Biochem 2008, 105:1117-1127
28. Gunawan B, von Heydebreck A, Fritsch T, Huber W, Ringert RH, Jakse G, Fuzesi L: Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 2003, 63:6200-6205 (Pubitemid 37255164)
29. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L: Genetic basis of cancer of the kidney: disease-specific approaches to therapy, Clin Cancer Res 2004, 10:6282S-6289S